The historical rank and industry rank for Neumora Therapeutics's Net Cash per Share or its related term are showing as below:
NMRA'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.8 Med: 5.52 Max: 6.34
Current: 3.8
During the past 5 years, the highest Price-to-Net-Cash Ratio of Neumora Therapeutics was 6.34. The lowest was 3.80. And the median was 5.52.
NMRA's Price-to-Net-Cash is ranked better than 51.66% of 871
companies
in the Biotechnology industry
Industry Median: 4.06
vs NMRA: 3.80
Neumora Therapeutics Net Cash per Share Historical Data
The historical data trend for Neumora Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neumora Therapeutics's Net Cash per Share
For the Biotechnology subindustry, Neumora Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neumora Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's Price-to-Net-Cash falls into.
Neumora Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Neumora Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neumora Therapeutics (NAS:NMRA) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Neumora Therapeutics Net Cash per Share Related Terms
Thank you for viewing the detailed overview of Neumora Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Neumora Therapeutics (Neumora Therapeutics) Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMRA has been successfully added to your 